Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 9016 to 9022 of 9022 results

  1. NICE publishes final draft guidance on Enhertu after commercial discussions conclude

    NICE does not recommend Enhertu (also called trastuzumab deruxtecan and made by Daiichi Sankyo) for treating advanced HER2-low breast cancer in adults.

  2. NICE recommended personalised immunotherapy to treat blood cancer in children and young adults to be made routinely available on the NHS

    Innovative CAR-T therapy recommended to treat an aggressive form of leukaemia.

  3. 170,000 people in England to have further treatment choice for preventing migraine attacks

    In final draft guidance published today NICE has recommended atogepant, the first of a new type of oral treatment option for preventing both chronic and episodic migraines, opening the way for up to 170,000 people to choose it on the NHS in England.

  4. Around 4,000 people with sickle cell disease could benefit from a new treatment recommended by NICE

    Improved deal signals NICE recommendation of sickle cell treatment voxelotor.

  5. 3 treatments for COVID-19 recommended in draft guidance

    Three treatments for COVID have been recommended in draft NICE guidance released today for public consultation.

  6. Listening to patients and organisations to update NICE's quality standard on transition from children's to adults' services

    Melanie explains how the update to our quality standard on the transition from children’s to adults’ services will benefit young people, their families and carers.

  7. NICE joins the shared commitment to public involvement in research

    Working alongside people and communities is an essential tool in helping to improve?the impact of our guidance and continuing to get the best care to people and communities, fast, while ensuring value for the taxpayer.